Biotech's Newest Wonders Could Be Cancer Killers

Researchers see so-called antisense drugs as the next wave of biotechnology. Unlike biotech clones of natural human antibodies or proteins such as insulin, antisense drugs can actually block the production of disease-causing enzymes by abnormal genes. At the end of August, the technology moved a step closer to practicality when Genta Inc., a tiny San Diego biotech company, filed the first application for human testing.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.